Greater US FDA And Manufacturer Transparency Recommended As Key to Supply Chain Resilience
Executive Summary
Manufacturers could risk losing FDA product approvals if they fail to publicize sourcing and quality information, under new proposals. National Academies expert panel says supply chain transparency – not a pandemic-induced rush to onshoring requirements – provides the framework to mitigate against and respond to drug shortages.
You may also be interested in...
Global Supply Chain Scrutiny And Investment In Domestic Alternatives For US Drug Shortages
Pharmaceutical supply chains may grow less efficient and less risk prone as US government gets more involved to ensure availability of pandemic and essential medicines. But what about pediatric oncology medicines and other treatments that save lives even though they may not be considered essential?
US FDA Needs ‘More Clout’ To Get Supply Chain Information, Califf Says
‘It’s driving me crazy that supply chains are a trade secret,’ FDA commissioner states. Agency also needs more clout to handle accelerated approvals, he tells gathering of industry executives and government policy makers.
US FDA Needs ‘More Clout’ To Get Supply Chain Information, Califf Says
‘It’s driving me crazy that supply chains are a trade secret,’ FDA commissioner states. Agency also needs more clout to handle accelerated approvals, he tells gathering of industry executives and government policy makers.